Q4 is behind us, and what the Boston Scientific investment thesis is now is the future, and particularly the future with Guidant. I expect, if they allow us, that's going to be the focus of the conference call. |
St. Jude has a very rich stock price right now. |
That (smaller market share) was expected. What wasn't expected is that the overall market is smaller than anticipated. |
The irony is, J&J could have had this company for $76 a share. |
The price that I think you'd have to pay for St. Jude would be even more expensive than what Guidant is being bid for today. |
The thing that's keeping this tennis match going longer is that both sides, if they can't have it, they really don't want the other guy to have it. |
There will be a lot of noise and statistics and science in their battle for market share, but in the end, I doubt things will change much. |
There's kind of an axiom out there that when Larry Best buys you should buy and when Larry Best sells you should sell. |
They are more bullish about their ability to pay down their debt than Wall Street had expected. |
They are not for sale, they are not looking to be for sale and they are happy doing what they are doing which is adding new products and growing like a weed. |
They are pushing the envelope. |
They are two very different businesses. |
They fell a little short of our aggressive ICD numbers. |
This is not one of those situations. This is just a difficult time the company will work itself through. |
Tobin being here full time is good ? you want someone with authority on site. That will make decision-making a lot faster. |